Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

UCLA researchers find link between brain cancer and fatty acid synthesis

UCLA researchers find link between brain cancer and fatty acid synthesis

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

Development of novel virus can lead to new therapeutic strategy to combat cancer

Development of novel virus can lead to new therapeutic strategy to combat cancer

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Clinical trials of personalised vaccines to fight glioblastomas

Clinical trials of personalised vaccines to fight glioblastomas

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Cancer promoting gene identified

Cancer promoting gene identified

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Erbitux recognized as one of the major clinical cancer advances of 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.